262 related articles for article (PubMed ID: 26697891)
41. Olanzapine and quetiapine use during breastfeeding: excretion into breast milk and safe breastfeeding strategy.
Aydin B; Nayir T; Sahin S; Yildiz A
J Clin Psychopharmacol; 2015 Apr; 35(2):206-8. PubMed ID: 25679127
[No Abstract] [Full Text] [Related]
42. Impact of extended-release quetiapine fumarate on hospitalization length and cost in schizophrenia and bipolar disorder patients: a retrospective, hospital-based, US-cohort analysis.
Locklear JC; Wahlqvist P; Gustafsson U; Udd M; Fajutrao L; Eriksson H
J Comp Eff Res; 2014 Jul; 3(4):335-44. PubMed ID: 25275231
[TBL] [Abstract][Full Text] [Related]
43. In vitro-in vivo correlation (IVIVC) models for metformin after administration of modified-release (MR) oral dosage forms to healthy human volunteers.
Balan G; Timmins P; Greene DS; Marathe PH
J Pharm Sci; 2001 Aug; 90(8):1176-85. PubMed ID: 11536222
[TBL] [Abstract][Full Text] [Related]
44. Impact of once-daily extended-release quetiapine fumarate on hospitalization length in patients with acute bipolar mania.
Bonafede M; Locklear JC; Wahlqvist P; Fajutrao L; Szamosi J; Pan K; Eriksson H
J Comp Eff Res; 2015 Jan; 4(1):51-9. PubMed ID: 25168473
[TBL] [Abstract][Full Text] [Related]
45. Treatment patterns, healthcare resource utilization and costs in patients with bipolar disorder, newly treated with extended release or immediate release quetiapine fumarate using US healthcare administrative claims data.
Locklear JC; Alemayehu B; Brody RS; Chavoshi S; Tunceli O; Kern D; Earley WR
Clin Ther; 2013 Dec; 35(12):1923-32. PubMed ID: 24275622
[TBL] [Abstract][Full Text] [Related]
46. The role of quetiapine extended release in the treatment of bipolar depression.
Cristancho MA; Thase ME
Adv Ther; 2010 Nov; 27(11):774-84. PubMed ID: 20835785
[TBL] [Abstract][Full Text] [Related]
47. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial.
Cutler AJ; Datto C; Nordenhem A; Minkwitz M; Acevedo L; Darko D
Clin Ther; 2011 Nov; 33(11):1643-58. PubMed ID: 22054797
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation.
Heinig R; Ahr G; Hayauchi Y; Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Aug; 35(8):341-51. PubMed ID: 9266290
[TBL] [Abstract][Full Text] [Related]
49. Bio-shielding In Situ Forming Gels (BSIFG) Loaded With Lipospheres for Depot Injection of Quetiapine Fumarate: In Vitro and In Vivo Evaluation.
Abo Elela MM; ElKasabgy NA; Basalious EB
AAPS PharmSciTech; 2017 Nov; 18(8):2999-3010. PubMed ID: 28493003
[TBL] [Abstract][Full Text] [Related]
50. In vitro/in vivo correlations of dissolution data of carbamazepine immediate release tablets with pharmacokinetic data obtained in healthy volunteers.
Lake OA; Olling M; Barends DM
Eur J Pharm Biopharm; 1999 Jul; 48(1):13-9. PubMed ID: 10477323
[TBL] [Abstract][Full Text] [Related]
51. Toward Biopredictive Dissolution for Enteric Coated Dosage Forms.
Al-Gousous J; Amidon GL; Langguth P
Mol Pharm; 2016 Jun; 13(6):1927-36. PubMed ID: 27139040
[TBL] [Abstract][Full Text] [Related]
52. Defining level A IVIVC dissolution specifications based on individual in vitro dissolution profiles of a controlled release formulation.
González-García I; García-Arieta A; Merino-Sanjuan M; Mangas-Sanjuan V; Bermejo M
Eur J Pharm Sci; 2018 Jul; 119():200-207. PubMed ID: 29680456
[TBL] [Abstract][Full Text] [Related]
53. Combined site-specific release retardant mini-matrix tablets (C-SSRRMT) for extended oral delivery of dexketoprofen trometamol:
Sweed NM; Basalious EB; Nour SA
Drug Dev Ind Pharm; 2019 Nov; 45(11):1777-1787. PubMed ID: 31418598
[TBL] [Abstract][Full Text] [Related]
54. Original research paper. Formulation and pharmaceutical development of quetiapine fumarate sustained release matrix tablets using a QbD approach.
Gavan A; Porfire A; Marina C; Tomuta I
Acta Pharm; 2017 Mar; 67(1):53-70. PubMed ID: 28231048
[TBL] [Abstract][Full Text] [Related]
55. Single-dose pharmacokinetics of methylphenidate extended-release multiple layer beads administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (Ritalin(®)) in healthy adult volunteers.
Adjei A; Teuscher NS; Kupper RJ; Chang WW; Greenhill L; Newcorn JH; Connor DF; Wigal S
J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):570-8. PubMed ID: 25514542
[TBL] [Abstract][Full Text] [Related]
56. In vitro-in vivo correlations for three different commercial immediate-release indapamide tablets.
Yaro P; He X; Liu W; Xun M; Ma Y; Li Z; Shi X
Drug Dev Ind Pharm; 2014 Dec; 40(12):1670-6. PubMed ID: 24102615
[TBL] [Abstract][Full Text] [Related]
57. In vitro-in vivo correlation of modified release dosage form of lamotrigine.
Shah HJ; Subbaiah G; Patel DM; Patel CN
Biopharm Drug Dispos; 2009 Dec; 30(9):524-31. PubMed ID: 19823969
[TBL] [Abstract][Full Text] [Related]
58. Influence of drug property and product design on in vitro-in vivo correlation of complex modified-release dosage forms.
Qiu Y; Li X; Duan JZ
J Pharm Sci; 2014 Feb; 103(2):507-16. PubMed ID: 24338862
[TBL] [Abstract][Full Text] [Related]
59. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression.
Suppes T; Datto C; Minkwitz M; Nordenhem A; Walker C; Darko D
J Affect Disord; 2010 Feb; 121(1-2):106-15. PubMed ID: 19903574
[TBL] [Abstract][Full Text] [Related]
60. Quetiapine extended release for the treatment of bipolar disorder.
Samalin L; Tremey A; Llorca PM
Expert Rev Neurother; 2014 Sep; 14(9):987-1005. PubMed ID: 25096854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
